Alice Gutteridge

Alice Gutteridge

Auto-generated profile, based on publicly available information

Alice Gutteridge

Cancer Institute, University College London, London, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2014 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Open access
PDF file
ADAlison S. Devonshire
Alison S. Devonshire
AWAlexandra S. Whale
Alexandra S. Whale
AGAlice Gutteridge
Alice Gutteridge
GJGerwyn Jones
Gerwyn Jones
SCSimon Cowen
Simon Cowen
JHJim Huggett
Jim Huggett
Circulating cell-free DNA (cfDNA) is becoming an important clinical analyte for prenatal testing, cancer diagnosis and cancer monitoring. The extraction stage is critical in ensuring clinical sensitivity of analytical methods measuring minority nucleic acid fractions, such as foetal-derived sequences in predominantly maternal cfDNA. Consequently, quality controls are required for measurement of extraction efficiency, fragment size bias and yield for validation of cfDNA methods. We evaluated the utility of an external DNA spike for monitoring these parameters in a study comparing three specific cfDNA extraction methods [QIAamp® circulating nucleic acid (CNA) kit, NucleoSpin® Plasma XS (NS) kit and FitAmp™ plasma/serum DNA isolation (FA) kit] with the commonly used QIAamp DNA blood mini (DBM) kit. We found that the extraction efficiencies of the kits ranked in the order CNA kit > DBM kit > NS kit > FA kit, and the CNA and NS kits gave a better representation of smaller DNA fragments in the extract than the DBM kit. We investigated means of improved reporting of cfDNA yield by comparing quantitative PCR measurements of seven different reference gene assays in plasma samples and validating these with digital PCR. We noted that the cfDNA quantities based on measurement of some target genes (e.g. TERT) were, on average, more than twofold higher than those of other assays (e.g. ERV3). We conclude that analysis and averaging of multiple reference genes using a GeNorm approach gives a more reliable estimate of total cfDNA quantity. Comparison of single and multiple reference gene normalisation for quantification of plasma cell free DNA

3 February 2015 in Analytical Chemistry
Verified
Journal Article
Closed access
ADAlison S. Devonshire
Alison S. Devonshire
IHIsobella Honeyborne
Isobella Honeyborne
AGAlice Gutteridge
Alice Gutteridge
AWAlexandra S. Whale
Alexandra S. Whale
GNGavin Nixon
Gavin Nixon
JHJim Huggett
Jim Huggett

1 October 2015 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
CSCarolina Salinas-Souza
Carolina Salinas-Souza
CACarlos De Andrea
Carlos De Andrea
MBMichel Bihl
Michel Bihl
MKMichal Kovac
Michal Kovac
NPNischalan Pillay
Nischalan Pillay
AFAdrienne M. Flanagan
Adrienne M. Flanagan

2 March 2015 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
FFF. Favero
F. Favero
NMN. McGranahan
N. McGranahan
MSM. Salm
M. Salm
ABAnd Nicolai J. Birkbak
And Nicolai J. Birkbak
JSJ. Z. Sanborn
J. Z. Sanborn
CSC. Swanton
C. Swanton
Glioblastoma (GBM) is the most common malignant brain cancer occurring in adults, and is associated with dismal outcome and few therapeutic options. GBM has been shown to predominantly disrupt three core pathways through somatic aberrations, rendering it ideal for precision medicine approaches. We describe a 35-year-old female patient with recurrent GBM following surgical removal of the primary tumour, adjuvant treatment with temozolomide and a 3-year disease-free period. Rapid whole-genome sequencing (WGS) of three separate tumour regions at recurrence was carried out and interpreted relative to WGS of two regions of the primary tumour. We found extensive mutational and copy-number heterogeneity within the primary tumour. We identified a TP53 mutation and two focal amplifications involving PDGFRA, KIT and CDK4, on chromosomes 4 and 12. A clonal IDH1 R132H mutation in the primary, a known GBM driver event, was detectable at only very low frequency in the recurrent tumour. After sub-clonal diversification, evidence was found for a whole-genome doubling event and a translocation between the amplified regions of PDGFRA, KIT and CDK4, encoded within a double-minute chromosome also incorporating miR26a-2. The WGS analysis uncovered progressive evolution of the double-minute chromosome converging on the KIT/PDGFRA/PI3K/mTOR axis, superseding the IDH1 mutation in dominance in a mutually exclusive manner at recurrence, consequently the patient was treated with imatinib. Despite rapid sequencing and cancer genome-guided therapy against amplified oncogenes, the disease progressed, and the patient died shortly after. This case sheds light on the dynamic evolution of a GBM tumour, defining the origins of the lethal sub-clone, the macro-evolutionary genomic events dominating the disease at recurrence and the loss of a clonal driver. Even in the era of rapid WGS analysis, cases such as this illustrate the significant hurdles for precision medicine success.

1 February 2017 in The Lancet
Verified
Journal Article
Open access
PDF file
JAJohn Apps
John Apps
GCGabriela Carreno
Gabriela Carreno
JBJessica Boult
Jessica Boult
AGAlice Gutteridge
Alice Gutteridge
LDLaura Danielson
Laura Danielson
JMJuan Pedro Martinez-Barbera
Juan Pedro Martinez-Barbera
Adamantinomatous craniopharyngiomas (ACP) are histologically benign but clinically aggressive tumours that lead to hypothalamic injury, visual impairment, and pituitary dysfunction. Histologically they consist of several compartments, and most cases have somatic CTNNB1-activating mutations. Similar functional activation of CTNNB1 in the developing murine pituitary gland results in murine ACP, study of which has given insight into human ACP (eg, showing activation of paracrine sonic hedgehog [SHH] signalling). We aimed to explore the genetic and transcriptional landscape of human ACP and test the functional significance of SHH signalling in vivo. RNA sequencing and targeted next generation DNA sequencing was done in ACP samples from local and national biobanks. Weighted gene correlation network analysis (WGCNA) was used to derive modules of coexpressed genes, and results were further refined with sequencing of laser capture microdissected tissue. A preclinical vehicle (n=11) controlled trial of the SHH pathway inhibitor GDC0449 (n=12) was performed in the embryonic mouse model of ACP. Next generation sequencing of laser capture microdissected tissue confirmed heterozygous CTNNB1 mutation in all tumour compartments but not reactive tissue. WGCNA identified expression signatures of different tissue components (eg, tumour epithelium, reactive tissue, and immune infiltrate) and identified novel ACP genes (eg, BCL11B). The tumour epithelium showed high expression of ameloblast transcription factors (eg, MSX2), and expression of enamel proteins (ENAM, AMELX, AMBN) correlated with the presence of wet keratin. RNA sequencing of laser capture microdissected tissue identified expression of SHH, transforming growth factor β1, bone morphogenic proteins, fibroblast growth factors, Wnt genes, and many cytokines and chemokines within tumour epithelial whorls and evidence of paracrine SHH signalling. Interim analysis of the GDC0449 trial suggests that inhibition of the SHH pathway might reduce survival in murine ACP (median survival 82 vs 233 days, p=0·1). Further studies showed that treatment with GDC0449 caused premature tumour induction, increased proliferation, and halved the doubling time of the solid tumour component as assessed by MRI. ACPs have clonal CTNNB1 mutations and share a common embryological origin with teeth. They exhibit a complex transcriptional landscape, including paracrine interactions between different cellular compartments. Studies of ACP murine models suggest that, as in pancreatic, colorectal, and bladder cancer models, caution is needed when considering the use of SHH pathway inhibitors as a treatment for human ACP. Cancer Research UK; Children with Cancer, Childhood Cancer and Leukaemia Group; Great Ormond Street Hospital Biomedical Research Centre.